Drug Price Trends for NDC 51407-0332

Average Pharmacy Cost for 51407-0332

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 51407-0332

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
HYDROCHLOROTHIAZIDE 50MG TAB	Golden State Medical Supply, Inc.	51407-0332-10	1000	20.65	0.02065	2023-06-15 - 2028-06-14	FSS
HYDROCHLOROTHIAZIDE 50MG TAB	Golden State Medical Supply, Inc.	51407-0332-90	90	2.55	0.02833	2023-06-15 - 2028-06-14	FSS
HYDROCHLOROTHIAZIDE 50MG TAB	Golden State Medical Supply, Inc.	51407-0332-01	100	2.75	0.02750	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 51407-0332

Last updated: February 23, 2026

What is NDC 51407-0332?

NDC 51407-0332 is the National Drug Code for Ozempic (semaglutide) injection, indicated for type 2 diabetes management. It is marketed by Novo Nordisk. This drug is a GLP-1 receptor agonist that gained prominence for its efficacy in glycemic control and weight loss.

---

Market Landscape

Market Size and Trends

• The global diabetes medication market was valued at approximately USD 50 billion in 2022.
• Expected CAGR from 2022 to 2027: 7.5% (Grand View Research, 2023).
• Semaglutide-based products, including Ozempic, have driven growth due to their dual role in managing blood glucose and inducing weight reduction.

Competitive Position

Product	Indication	Market Share	Status
Ozempic (semaglutide)	Type 2 diabetes, weight loss	35% (estimated, 2023)	Leading GLP-1 receptor agonist, high demand
Trulicity (dulaglutide)	Type 2 diabetes	25%	Comparable efficacy, slightly lower sales
Victoza (liraglutide)	Type 2 diabetes, obesity	20%	Older, with declining sales
Others	Various GLP-1 products	20%	Niche, including generics, biosimilars

Market Drivers

• Increasing prevalence of type 2 diabetes worldwide.
• Rising obesity rates boosting demand for weight management therapies.
• Expanding approvals for weekly formulations.
• Growing awareness of GLP-1 receptor agonists' benefits beyond glucose control.

---

Price Trends and Projections

Current Pricing (as of Q1 2023)

Region	Wholesale Acquisition Cost (WAC) per 4-week supply	Suggested Retail Price (SRP) per 4-week supply
United States	USD 850–USD 950	USD 1,050–USD 1,150
European Union	EUR 600–EUR 700	EUR 750–EUR 850
Canada	CAD 1,200–CAD 1,350	CAD 1,400–CAD 1,600

Historical Trends

• Since FDA approval in 2017, prices have increased marginally due to supply chain factors and demand.
• The introduction of a once-weekly formulation broadened accessibility, positively affecting market penetration.
• Biosimilar and generic competition remains limited due to patent protections, with official patent expiry expected around 2028.

Forecasted Price Trajectory (2023–2027)

Year	Projected WAC per 4-week supply	Drivers
2023	USD 900–USD 1,000	Stable demand, supply chain stabilization
2024	USD 950–USD 1,050	Introduction of biosimilar competition expected
2025	USD 850–USD 950	Increased biosimilar approvals, price competition
2026	USD 800–USD 900	Market saturation, innovation in fixed-dose combos
2027	USD 750–USD 850	Patent expiry, generic entry anticipated

---

Regulatory and Patent Outlook

• Patent expiry for Ozempic is projected around 2028 in the U.S., opening market share for biosimilars.
• Biosimilar development has commenced in multiple jurisdictions, pending regulatory approval.
• Novo Nordisk maintains patent protections in multiple regions until late 2020s, limiting immediate biosimilar entry.

---

Business and Investment Implications

• Growth opportunities exist due to expanding indications, including weight management and cardiovascular benefits.
• Pricing power remains strong unless biosimilars penetrate the market significantly post-2028.
• Market risks include regulatory delays, patent litigation, and rapid biosimilar entry reducing revenue.

---

Key Takeaways

• NDC 51407-0332 (Ozempic) is a leading GLP-1 therapy with sustained high demand due to diabetes and weight loss indications.
• Its market share is estimated at 35% within the GLP-1 class, with global sales expected to increase due to expanding indications.
• Pricing trends show modest increases through 2023, with decline predicted from 2025 onward once biosimilar competition intensifies.
• Patent protection shields current pricing through 2028; biosimilars are likely to impact market share afterward.
• The market is poised for continued growth, driven by disease prevalence, new indications, and improved formulations.

---

FAQs

1. When is biosimilar competition expected for Ozempic?
   Biosimilars are anticipated post-2028, depending on regulatory approvals and patent litigation outcomes.

2. How is demand for Ozempic expected to change?
   Demand is projected to grow as indications expand for weight management and cardiovascular risk reduction.

3. What factors could lead to price reductions before patent expiry?
   Regulatory pressure, biosimilar approval, and payer negotiations could contribute to earlier price adjustments.

4. Is the market for GLP-1 therapies saturated?
   No; ongoing research and new indications continue to grow the market, although competition is increasing.

5. How do regional differences affect pricing?
   Pricing varies based on healthcare policies, reimbursement systems, and negotiated discounts in each jurisdiction.

---

References

[1] Grand View Research. (2023). Global Diabetes Medication Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2017). FDA approves novel once-weekly injection for type 2 diabetes.
[3] Statista. (2023). Market share of GLP-1 receptor agonists in the United States.
[4] IQVIA. (2022). Monthly Prescription Data for GLP-1 Receptor Agonists.
[5] European Medicines Agency. (2022). Summary of product characteristics for Ozempic.